Samantha Schubert1, Cristian E Leyton1,2,3, John R Hodges1,3,4, Olivier Piguet1,3,4. 1. Neuroscience Research Australia, NSW, Australia. 2. The Faculty of Health Sciences, The University of Sydney, NSW, Australia. 3. ARC Centre of Excellence in Cognition and its Disorders, Sydney, NSW, Australia. 4. School of Medical Sciences, The University of New South Wales, Sydney, NSW, Australia.
Abstract
BACKGROUND: Alzheimer's disease (AD) and behavioral-variant of frontotemporal dementia (bvFTD) can present with an overlapping neuropsychological profile, which often hinders their clinical differentiation. OBJECTIVE: To compare changes over time in memory, general cognition tasks, and functional scales between bvFTD and AD. METHODS: Consecutive cases diagnosed with probable bvFTD (n = 22) and typical AD (n = 31) with at least two clinical visits were selected. Of these, 13 (9 AD, 4 bvFTD) underwent Pittsburgh compound B PET scan, which supported the clinical diagnosis in all cases. Mixed-model regressions were used to estimate the differential rate of decline on selected tasks between cohorts. RESULTS: Analyses demonstrated that, despite equivalent baseline performance, bvFTD patients experienced a more rapid functional deterioration and a steeper decline in global cognition than AD patients. At baseline, both groups were impaired on executive function and memory tasks compared to controls, but these deficits were more marked in the bvFTD group. In addition, performance on these domains continued to decline more rapidly in this group. CONCLUSIONS: Neither the initial neuropsychological assessment nor projected performances can reliably distinguish the totality of bvFTD and AD individuals. Nevertheless, annual rates of progression on cognitive tasks provide valuable information and will potentially help establish the impact of future therapeutic treatments in these dementia syndromes.
BACKGROUND:Alzheimer's disease (AD) and behavioral-variant of frontotemporal dementia (bvFTD) can present with an overlapping neuropsychological profile, which often hinders their clinical differentiation. OBJECTIVE: To compare changes over time in memory, general cognition tasks, and functional scales between bvFTD and AD. METHODS: Consecutive cases diagnosed with probable bvFTD (n = 22) and typical AD (n = 31) with at least two clinical visits were selected. Of these, 13 (9 AD, 4 bvFTD) underwent Pittsburgh compound B PET scan, which supported the clinical diagnosis in all cases. Mixed-model regressions were used to estimate the differential rate of decline on selected tasks between cohorts. RESULTS: Analyses demonstrated that, despite equivalent baseline performance, bvFTD patients experienced a more rapid functional deterioration and a steeper decline in global cognition than ADpatients. At baseline, both groups were impaired on executive function and memory tasks compared to controls, but these deficits were more marked in the bvFTD group. In addition, performance on these domains continued to decline more rapidly in this group. CONCLUSIONS: Neither the initial neuropsychological assessment nor projected performances can reliably distinguish the totality of bvFTD and AD individuals. Nevertheless, annual rates of progression on cognitive tasks provide valuable information and will potentially help establish the impact of future therapeutic treatments in these dementia syndromes.
Authors: Maxime Bertoux; Marie Sarazin; Florence Pasquier; Michel Bottlaender; Leonardo Cruz de Souza; Eneida Mioshi; Michael Hornberger; Kamalini G Ranasinghe; Katherine P Rankin; Iryna V Lobach; Joel H Kramer; Virginia E Sturm; Brianne M Bettcher; Katherine Possin; S Christine You; Amanda K Lamarre; Tal Shany-Ur; Melanie L Stephens; David C Perry; Suzee E Lee; Zachary A Miller; Maria L Gorno-Tempini; Howard J Rosen; Adam Boxer; William W Seeley; Gil D Rabinovici; Keith A Vossel; Bruce L Miller Journal: Neurology Date: 2016-10-04 Impact factor: 9.910
Authors: Lucy Vivash; Charles B Malpas; Christian Meletis; Meghan Gollant; Dhamidhu Eratne; Qiao-Xin Li; Stuart McDonald; William T O'Brien; Amy Brodtmann; David Darby; Christopher Kyndt; Mark Walterfang; Christopher M Hovens; Dennis Velakoulis; Terence J O'Brien Journal: Alzheimers Dement (N Y) Date: 2022-05-05
Authors: Adam M Staffaroni; Peter A Ljubenkov; John Kornak; Yann Cobigo; Samir Datta; Gabe Marx; Samantha M Walters; Kevin Chiang; Nick Olney; Fanny M Elahi; David S Knopman; Bradford C Dickerson; Bradley F Boeve; Maria Luisa Gorno-Tempini; Salvatore Spina; Lea T Grinberg; William W Seeley; Bruce L Miller; Joel H Kramer; Adam L Boxer; Howard J Rosen Journal: Brain Date: 2019-02-01 Impact factor: 13.501
Authors: Megan S Barker; Masood Manoochehri; Sandra J Rizer; Brian S Appleby; Danielle Brushaber; Sheena I Dev; Katrina L Devick; Bradford C Dickerson; Julie A Fields; Tatiana M Foroud; Leah K Forsberg; Douglas R Galasko; Nupur Ghoshal; Neill R Graff-Radford; Murray Grossman; Hilary W Heuer; Ging-Yuek Hsiung; John Kornak; Irene Litvan; Ian R Mackenzie; Mario F Mendez; Belen Pascual; Katherine P Rankin; Katya Rascovsky; Adam M Staffaroni; Maria Carmela Tartaglia; Sandra Weintraub; Bonnie Wong; Bradley F Boeve; Adam L Boxer; Howard J Rosen; Jill Goldman; Edward D Huey; Stephanie Cosentino Journal: Cortex Date: 2021-03-19 Impact factor: 4.644
Authors: Mario Amore Cecchini; Mônica Sanches Yassuda; Valéria Santoro Bahia; Leonardo Cruz de Souza; Henrique Cerqueira Guimarães; Paulo Caramelli; Maria Teresa Carthery-Goulart; Flávia Patrocínio; Maria Paula Foss; Vitor Tumas; Thaís Bento Lima-Silva; Sônia Maria Dozzi Brucki; Ricardo Nitrini; Sergio Della Sala; Mario A Parra Journal: J Neurol Date: 2017-09-11 Impact factor: 4.849